What Are the Symptoms of Candida Auris?

Candida auris does not produce a unique set of symptoms that would immediately tip off a patient or clinician. Instead, its clinical signs mimic those of many other bacterial and fungal infections: fever, chills, fatigue, and general signs of systemic illness. What makes this fungus alarming is not a distinctive symptom profile but rather the combination of diagnostic difficulty, drug resistance, and a tendency to spread silently through healthcare settings before anyone realizes it is present.

Colonization Versus Active Infection

Before talking about symptoms, it helps to understand that many people carrying C. auris have no symptoms at all. The fungus can live on the skin, particularly in warm, moist areas like the groin, armpits, and nostrils, without causing any disease. This silent carriage is called colonization, and it is the most common way hospitals first detect the organism during screening swabs. A murine study demonstrated that skin colonization is typically asymptomatic but often precedes bloodstream infection, meaning it functions as a risk factor rather than an illness in itself.¹ In surveillance programs, healthcare workers swab sites like the nose, throat, axilla, groin, perineum, and rectum to catch colonized patients early.²

The transition from colonization to infection usually requires something to go wrong with the body’s defenses: a weakened immune system, a break in the skin from a surgical wound, or a medical device like a catheter creating a direct path into the bloodstream. You can carry C. auris for weeks or months without knowing it, and many colonized patients never develop an active infection. But when infection does develop, the symptoms depend almost entirely on where in the body the fungus takes hold.

What Symptoms Look Like by Infection Site

C. auris can infect a surprisingly wide range of body sites. The most common and most dangerous presentation is candidemia, a bloodstream infection. Other documented infection types include central venous catheter infections, wound and soft tissue infections, burn infections, bone infections, heart infections, meningitis, and urinary tract infections.³ Because these sites are so varied, the symptoms span a wide range:

Bloodstream infection: Fever that does not respond to antibiotics is the hallmark warning sign. Patients may also develop low blood pressure, rapid heart rate, and confusion, progressing to septic shock in severe cases.
Wound infections: Redness, swelling, warmth, and pus around surgical sites or burns. These signs overlap completely with bacterial wound infections.
Urinary tract infections: Cloudy or foul-smelling urine, pain during urination, and sometimes fever. C. auris urine isolates are frequently found in patients with urinary catheters and are linked to high mortality rates.⁴
Ear infections: Ear discharge, which tends to be purulent or serous. A study of 79 patients with C. auris ear infections in South Korea found that roughly 60% had purulent discharge and 34% had serous discharge.⁵
Meningitis: Severe headache, neck stiffness, sensitivity to light, and altered mental status.

The ear infection finding is worth pausing on because C. auris was originally identified from the ear canal of a patient in Japan in 2009. Ear infections caused by this organism are not life-threatening in the same way bloodstream infections are, but they illustrate how the fungus can appear in unexpected places and go unrecognized for years.

The Persistent Fever Problem

If there is one clinical scenario that should raise suspicion for C. auris, it is a fever that will not break despite appropriate antibiotic treatment. This pattern, sometimes described as persistent fever unresponsive to antibiotics, is a classic red flag for invasive fungal infections generally.⁶ In an ICU patient with central lines, catheters, and broad-spectrum antibiotics on board, a fever that persists for days without an obvious bacterial source should prompt clinicians to consider a fungal culprit.

The trouble is that this scenario is common. ICU patients develop unexplained fevers frequently, and many of those fevers turn out to be caused by drug-resistant bacteria, viral reactivation, or non-infectious inflammation. There is nothing about a C. auris fever that distinguishes it clinically from these other causes. The diagnosis depends on laboratory confirmation, not on the pattern of symptoms.

Why Diagnosis Is So Difficult

One of the most frustrating aspects of C. auris is that standard laboratory methods often misidentify it as a different Candida species entirely.⁷ Conventional biochemical tests used in many clinical labs cannot reliably distinguish C. auris from closely related species like Candida haemulonii or Candida duobushaemulonii. More advanced identification methods, such as mass spectrometry with updated databases or molecular testing, are needed for accurate identification. Many labs, particularly in resource-limited settings, do not have this equipment.

This matters for patients because misidentification can lead to inappropriate treatment. If C. auris is labeled as a less resistant Candida species, a doctor might prescribe a standard antifungal that the organism shrugs off, giving the infection more time to establish itself. The nonspecific symptoms compound the problem: invasive candidiasis in the ICU is already one of the hardest infections to diagnose because its clinical signs overlap with so many other conditions, and the organism frequently colonizes patients without causing disease.¹

Who Is Most Likely to Develop Symptoms

C. auris overwhelmingly targets people who are already seriously ill. The typical patient is someone in an intensive care unit or a long-term care facility with multiple medical devices and a compromised immune system. Key risk factors include mechanical ventilation, central venous lines, feeding tubes, urinary catheters, prolonged healthcare stays, and colonization with other drug-resistant organisms.⁸

Indwelling medical devices deserve special attention. A study of patients in Saudi Arabia found that having a urinary catheter or central venous line upon hospital admission more than doubled the risk of C. auris colonization or infection.⁹ These devices provide a direct highway for the fungus to bypass the skin barrier and enter the bloodstream or urinary tract. If you are visiting a hospitalized family member or navigating your own hospital stay, the presence of these devices is worth being aware of, not to cause alarm, but to understand why infection-control measures around them matter so much.

Healthy people in the community face virtually no risk. C. auris is not a pathogen that attacks people with intact immune systems going about their daily lives. Its victims are almost exclusively people who are already medically fragile, and the infections happen within healthcare settings rather than in homes or public spaces.

Drug Resistance and Why It Complicates the Picture

The symptoms of a C. auris infection are not inherently worse than those of other Candida infections. What makes C. auris dangerous is that once you have symptoms, the infection may be unusually difficult to treat. Most C. auris isolates are resistant to fluconazole, the workhorse antifungal used for common yeast infections, and many are resistant to additional drug classes as well.¹⁰ Isolates resistant to all major classes of available antifungals have been reported.¹¹

From the patient’s perspective, this resistance manifests as symptoms that persist or worsen despite antifungal treatment. A bloodstream infection that should clear within days may linger. Fevers continue. Blood cultures remain positive. Clinicians have to switch drugs, sometimes multiple times, and the fungus can develop new resistance mechanisms even during therapy through genetic mutations and chromosomal changes.¹² It is this capacity to evolve resistance in real time that sets C. auris apart from most other fungal pathogens and makes persistent symptoms a more ominous sign than they would be with a typical Candida infection.

Mortality and What the Numbers Actually Show

Headlines about C. auris often emphasize frightening mortality rates, and the numbers are indeed sobering but deserve context. A systematic review and meta-analysis of global data found an overall mortality rate for C. auris infection of about 39%, with bloodstream infections carrying a higher rate of roughly 45%.¹³ In Europe, the figure was closer to 20%, suggesting that outcomes vary considerably by region, likely reflecting differences in healthcare resources and surveillance.

Those numbers can mislead if you take them at face value, because the patients who develop C. auris bloodstream infections are already among the sickest people in any hospital. A multicentre retrospective study comparing C. auris candidemia to candidemia caused by other Candida species found that 30-day crude mortality was actually lower in the C. auris group (about 38%) than in the non-auris group (about 51%), and after adjusting for other factors, C. auris patients had lower mortality risk. Antifungal treatment itself substantially reduced mortality, while septic shock increased it.¹⁴ A smaller study in Illinois found that among 12 inpatients treated for C. auris infections, about 83% met criteria for clinical success at 30 days.¹⁵

The takeaway here is not that C. auris is harmless. It is that the high crude mortality partly reflects the extreme vulnerability of the patients it infects rather than some extraordinary lethality unique to this species. When appropriate antifungal treatment is given promptly, many patients do survive. The danger lies in delayed diagnosis, drug resistance that limits treatment options, and the fragile baseline health of most affected patients.

How C. Auris Spreads in Healthcare Facilities

Understanding transmission helps explain why symptoms tend to cluster in specific healthcare settings rather than appearing randomly. C. auris is unusually durable on environmental surfaces. It can survive on plastic healthcare surfaces for at least 14 days under conditions typical of a hospital room.¹⁶ On a broader range of surface materials, including metal, glass, and wood, it has been shown to survive for more than three weeks in both wet and dry conditions, and it thrives in biofilm form on all tested surfaces.¹⁷

This environmental persistence means the fungus can lurk on bedrails, medical equipment, and countertops long after an infected patient has left a room. Standard cleaning may not eliminate it. Healthcare workers can transfer it between patients on their hands or gloves. Outbreaks tend to occur in ICUs, long-term acute care hospitals, and nursing facilities where patients have extended stays, frequent device use, and heavy antibiotic exposure. Unlike most other Candida species, C. auris appears to be commonly transmitted within healthcare facilities and causes healthcare-associated outbreaks.¹⁶

C. Auris in Children and Newborns

Most of the attention around C. auris focuses on adult ICU patients, but the fungus also affects pediatric populations, particularly newborns in neonatal intensive care units. In children, bloodstream infection is the dominant presentation, accounting for about 94% of pediatric C. auris cases in one review, with a median time from hospital admission to isolation of about 20 days.¹⁸

A key finding from neonatal studies is that the clinical features of C. auris sepsis are indistinguishable from sepsis caused by other organisms.¹⁹ Newborns with sepsis of any cause present with similar signs: temperature instability, feeding intolerance, lethargy, respiratory distress, and sometimes abdominal distension. There is no clinical shortcut to distinguishing C. auris from bacterial sepsis or sepsis caused by other Candida species in a neonate. Diagnosis depends entirely on blood cultures and correct laboratory identification.

How C. Auris Behaves Differently on the Skin

One of the more intriguing aspects of C. auris is its unusual affinity for skin. While Candida albicans, the most familiar yeast pathogen, tends to colonize mucosal surfaces like the mouth and gut, C. auris has a strong preference for skin tissue. Research using mouse models has shown that C. auris provokes a weaker immune response in the skin compared to C. albicans, which helps explain why the organism persists on skin for so long without being cleared by the body’s defenses.²⁰ In practical terms, this skin tropism is the engine behind the persistent colonization that makes healthcare outbreaks so difficult to control. Patients shed the fungus from their skin onto surfaces, devices, and the hands of healthcare workers.

In animal virulence studies, C. auris sits in a middle tier. It was less virulent than C. albicans, which produced higher mortality in infected mice, but it was more virulent than some less common Candida species. Notably, there was no statistically significant difference in fungal burden between C. auris and C. albicans in the kidneys, spleen, liver, and lungs of infected mice, suggesting the organism is capable of causing serious invasive disease even if it does not consistently reach the virulence levels of C. albicans.²¹

The Strain Variation Problem

C. auris is not a single uniform organism. It exists in multiple genetically distinct groups, called clades, that emerged on different continents and have followed different evolutionary paths. These clades can differ in their drug resistance profiles, their tendency to spread, and possibly their ability to cause disease.²² This genetic diversity means that a C. auris outbreak in one region may behave differently from an outbreak elsewhere, not just in terms of which drugs work against it, but potentially in how aggressively it infects patients and how easily it spreads.

For the average person, this variation helps explain why mortality figures and resistance rates in the published literature vary so widely from study to study. A hospital dealing with a highly resistant clade will have a very different experience from one encountering a more drug-susceptible strain. It also means that generalizations about C. auris symptoms and outcomes always carry an asterisk: the specific clade involved matters, and we are still learning exactly how much it matters for clinical presentation. The research picture continues to sharpen, but this pathogen’s diversity is one reason why simple, universal answers about what to expect from a C. auris infection remain elusive.

1
PubMed Central. Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies
2
PubMed Central. Screening for Candida auris in patients admitted to eight intensive care units in England, 2017 to 2018
3
PubMed. Candida auris: A focused review for emergency clinicians
4
PubMed Central. Candida auris is emerging as a prevalent urinary pathogen
5
PubMed. Candida auris colonization or infection of the ear: A single-center study in South Korea from 2016 to 2018
6
Current Biotechnology. Candidiasis in the Era of COVID-19: Challenges, Treatment Approaches, and Research Priorities
7
PubMed. Methods for identification of Candida auris, the yeast of global public health concern: A review
8
Journal of Translational Critical Care Medicine. Candida auris in intensive care unit: A growing clinical concern
9
Infection and Drug Resistance. Risk Factors for Candidozyma auris Among Admitted Patients in Riyadh, Saudi Arabia (2020–2022)
10
PubMed Central. Deciphering the multidrug resistance paradigm in Candida auris
11
PubMed Central. The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris
12
PubMed Central. Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance
13
PubMed Central. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris
14
PubMed Central. Mortality Caused by Candida auris Bloodstream Infections in Comparison with Other Candida Species, a Multicentre Retrospective Cohort
15
PubMed Central. Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, Illinois, USA
16
PubMed Central. Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface
17
PubMed. Survival of Candida auris on environmental surface materials and low-level resistance to disinfectant
18
PubMed. Candida (Candidozyma) auris in pediatric population: risk factors, clinical presentation, and outcomes
19
PubMed. Neonatal Candida auris infection: Management and prevention strategies – A single centre experience
20
PubMed Central. Differential skin immune responses in mice intradermally infected with Candida auris and Candida albicans
21
PubMed. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model
22
PubMed Central. The many faces of Candida auris: Phenotypic and strain variation in an emerging pathogen